FLARAXIN Infusions are anti-cancer, antiviral, anti-inflammatory, immuno-modulatory, stimulates the production of interferon, reduces allergic reactions, suppresses the development of pathogenic microflora and strengthens the protective properties of the body. This form is most efficient against cancer and other internal diseases.
Includes Patient Questionnaire used for consultation.
Do not use without prescription.
FLARAXIN injections are antitumoral, antiviral herbal medication, which stimulates the production of alpha, beta and gamma interferons, tumor necrosis and acts as a protector of normal cells during the chemotherapy process. It possesses anti-oxidant properties. It reduces toxins and overall intoxication, and is safe in application. Prevents relapse of the disease. In most cases manages to achieve the regression of tumours and destroy metastasises. Prevents relapse of the disease.
FLARAXIN is effective on benign and malignant tumours of all stages (I-IV): brain cancer (glioma, ependymoma, oligodendroglioma, etc.); skin cancer (melanoblastoma, melanoma, basalium, etc.); lung cancer, breast cancer, pharyngeal and laryngeal cancer, esophagus cancer, stomach cancer, intestinal cancer, kidney cancer (adenocarcinoma); bladder cancer, prostate cancer, cancer of the female genital area (uterus, cervix, ovaries); lymphogranulomatosis and leukemia; benign tumours (fibromyoma of the uterus, polycystic ovaries, mastopathy, adenoma, polyposis of various organs, etc.) Also efficient in complex treatment of Viral Hepatitis A, B, C, Herpes, Cytomegalovirus infections.
When combined with chemotherapy and radiotherapy, the drug enhances the effects on cancerous cells and reduces damage to normal cells.
FLARAXIN is compatible with most drugs, except ones containing iron.
Please refer to our Treatment page for more details on treatment of patients with Cancer in combination with other treatments and medicines or alone, after or before Chemotherapy and frequently asked questions pertaining to treatment.
Flaraxin can be used in:
The treatment of cancer in combination with chemotherapy and radiotherapy;
Patients that do not have the possibility to use traditional methods of cancer treatment;
Immune system correction in persons suffering from secondary immune deficiency;
In mono and complex therapies of benign and malignant neoplasms.
FLARAXIN normalizes the immunological background in cancer patients; Normalizes the ratio of immune-competent Cd4 / Cd8 cells (helper suppressors) and increases the number of natural killers (NK-cells). Immunobiochemical research has established FLARAXIN’s ability to bind with cancer proteins, causing micro-denaturation damage to them. The cancerostatic effect is caused due to the influence of FLARAXIN on the metabolism of cancerous cells, causing their death. Positive therapeutic effects in patients with advanced forms of cancer include restraining of metastatic activity and elimination of autoimmune disorders; substantially improving the quality of the lives of patient of this category.
FLARAXIN can be used in various clinical and morphological forms of malignant neoplasms, treatment of benign tumours, and as a cancerostatic and anti-reccurent medication. The combining of FLARAXIN with chemotherapy and radiotherapy is clinically approved, it is as well effective to use FLARAXIN in adjuvant and non-adjuvant therapy. In the former case the conditions for an effective surgical operation are created. While in the latter case, the need to continue prophylactic chemotherapeutic treatments ceases. FLARAXIN actively binds to pathological immune complexes and is able to prevent the progression of autoimmune diseases in the pathogenesis, in which immune complexes are formed (cirrhosis, hepatitis, chronic nephritis, etc.) The aforementioned properties of FLARAXIN grant you the ability to use it in the treatment of viral infections of the CNS, slow viral infections (which include AIDS, multiple sclerosis, etc.)
It is advisable to use FLARAXIN in various combinations with radiation and chemotherapy. It is clinically justified and highly effective to use it as a means of adjuvant and neoadjuvant therapy. In the first case, prerequisites for successful surgical intervention are created, in the second case, there is no need for preventive chemotherapy treatment.
The above properties of the medicine make it possible to use FLARAXIN in the treatment of viral infections of the central nervous system and "slow" viral infections (which include AIDS, multiple sclerosis, etc).
1 vial contains 150 mg of lyophilized phenol powder of herbal origin, tannin, vitamins C, E, potassium iodide.
FLARAXIN Injections are contraindicated in pregnant women, for acute renal and hepatic insufficiency and in cases of intolerance to iodine-containing drugs.
With increased sensitivity at the site of administration, phlebitis can develop.
Store dry powder at 20°C to 25°C. Protect from light.
Form of Issue
Lyophilized powder of 150 mg in vials (4 vials in one box).